Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Berry

Showing results (171-180 of 312) with videos related to

Pageof 32
Sort By:
Scientific Reports|November 20, 2018
Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescentsRandi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, et al.
Cancer Immunology Research|February 5, 2015
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral CenterDouglas B Johnson, Debra L Friedman, Elizabeth Berry, et al.
Journal of Neurodevelopmental Disorders|April 4, 2020
Correction to: Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validityLeonard Abbeduto, Elizabeth Berry-Kravis, Audra Sterling, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|January 11, 2022
A Pilot Educational Intervention to Support Primary Care Provider Performance of Skin Cancer ExaminationsKelly C Nelson, Elizabeth V Seiverling, Nadeen Gonna, et al.
Journal of Neurodevelopmental Disorders|March 25, 2020
Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validityLeonard Abbeduto, Elizabeth Berry-Kravis, Audra Sterling, et al.
Journal of Neurodevelopmental Disorders|February 9, 2016
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension studyDonald B Bailey, Elizabeth Berry-Kravis, Anne Wheeler, et al.
Journal of Neurodevelopmental Disorders|October 18, 2019
Vocabulary comprehension in adults with fragile X syndrome (FXS)Anne Hoffmann, Sue Ellen Krause, Joanne Wuu, et al.
The Biochemical Journal|June 2, 2010
Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndromeCatherine Ross-Inta, Alicja Omanska-Klusek, Sarah Wong, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 5, 2022
Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1Neena Agrawal, Nicole Y Farhat, Ninet Sinaii, et al.
The Journal of Molecular Diagnostics : JMD|May 18, 2013
Development of a genomic DNA reference material panel for myotonic dystrophy type 1 (DM1) genetic testingLisa Kalman, Jack Tarleton, Monica Hitch, et al.
Pageof 32

Showing results (171-180 of 312) with videos related to

Sort By:
Pageof 32
Scientific Reports|November 20, 2018
Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescentsRandi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, et al.
Cancer Immunology Research|February 5, 2015
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral CenterDouglas B Johnson, Debra L Friedman, Elizabeth Berry, et al.
Journal of Neurodevelopmental Disorders|April 4, 2020
Correction to: Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validityLeonard Abbeduto, Elizabeth Berry-Kravis, Audra Sterling, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|January 11, 2022
A Pilot Educational Intervention to Support Primary Care Provider Performance of Skin Cancer ExaminationsKelly C Nelson, Elizabeth V Seiverling, Nadeen Gonna, et al.
Journal of Neurodevelopmental Disorders|March 25, 2020
Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validityLeonard Abbeduto, Elizabeth Berry-Kravis, Audra Sterling, et al.
Journal of Neurodevelopmental Disorders|February 9, 2016
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension studyDonald B Bailey, Elizabeth Berry-Kravis, Anne Wheeler, et al.
Journal of Neurodevelopmental Disorders|October 18, 2019
Vocabulary comprehension in adults with fragile X syndrome (FXS)Anne Hoffmann, Sue Ellen Krause, Joanne Wuu, et al.
The Biochemical Journal|June 2, 2010
Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndromeCatherine Ross-Inta, Alicja Omanska-Klusek, Sarah Wong, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 5, 2022
Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1Neena Agrawal, Nicole Y Farhat, Ninet Sinaii, et al.
The Journal of Molecular Diagnostics : JMD|May 18, 2013
Development of a genomic DNA reference material panel for myotonic dystrophy type 1 (DM1) genetic testingLisa Kalman, Jack Tarleton, Monica Hitch, et al.
Pageof 32